HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 16.
Investments in associates and joint ventures A loss of $2 million representing the Group share of the results of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Co. Ltd 2014: share of loss $6 million.
During 2015, the Group has impaired the remaining investment balance related to Unimark Remedies Limited of $7 million which is due to the continuous financial difficulties.
Hikmas share in Unimark Remedies Limited is being divested during 2016 for minimal value.
The below represents the Groups share of the result and the impairment of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Co. Ltd.
Both are included in the consolidated income statement.
For the year ended For the year ended 31 December 2015 31 December 2014 Joint Joint Associates Total ventures Associates Total ventures $m $m $m $m $m $m Balance at 1 January 3 13 16 3 19 22 Share of loss 2 2 6 6 Impairment of investment note 5 7 7 Balance at 31 December 3 4 7 3 13 16 Summarised financial information in respect of the Groups interests in associated companies is set out below: For the year For the year ended ended 31 December 31 December 2015 2014 $m $m Total assets 214 220 Total liabilities 160 148 Net assets 54 72 Group's share of net assets of associates 13 17 Total revenue 49 50 Net loss 23 27 Group's share of loss of associates 2 6 17.
Deferred tax The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting years.
Other short-term Deferred R&D temporary Amortisable Share-based Tax losses costs differences assets Fixed assets payments Total $m $m $m $m $m $m $m At 1 January 2014 1 89 22 9 1 60 Charge Credit to income 4 12 1 7 Acquisition of business 13 13 Exchange differences 2 2 At 1 January 2015 4 1 77 20 22 2 42 Credit Charge to income 1 3 1 6 5 Charge to equity 1 1 Remeasurement note 43 2 2 Exchange differences 1 1 1 1 At 31 December 2015 4 1 74 18 13 1 49 160 160
